COVID-19 mRNA vaccine - Biocad
Latest Information Update: 25 Dec 2021
At a glance
- Originator Biocad
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 26 Mar 2020 COVID-19 mRNA vaccine - BIOCAD is available for licensing as of 23 Mar 2020. https://biocadglobal.com/partnership.html
- 23 Mar 2020 Early research in COVID-2019 infections (Prevention) in Russia (parenteral)
- 19 Mar 2020 Biocad plans a first preclinical trial in COVID-2019 infections (Prevention) in April 2020
Development Overview
Introduction
An mRNA based vaccine to prevent SARS-COV-2 (COVID-2019) coronavirus infections is being developed by Biocad. Early research is underway in the Russia.
Biocad is looking partnership opportunities for the development of the vaccine (BIOCAD website, March 2020).
Key Development Milestones
As of March 2020, early research is ongoing in Russia for COVID-19 vaccine [1] .
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class COVID-19 vaccines, RNA vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07B (Viral Vaccines)
-
EPhMRA code
J7E (Viral Vaccines)
Biomarker
Drug Name | Biomarker Name | Biomarker Function |
---|---|---|
COVID-19 mRNA vaccine - Biocad | C-reactive protein (CRP) | Outcome Measure |
CBLIF | Outcome Measure | |
elaC ribonuclease Z 1 | Detailed Description, Outcome Measure | |
Glycerophosphocholine | Eligibility Criteria | |
Interferon alpha (IFN-alpha) | Outcome Measure | |
Interferon Gamma (IFNg) | Outcome Measure | |
Interleukin-2 (IL-2) | Outcome Measure | |
Interleukin-4 (IL-4) | Outcome Measure | |
Protein S | Outcome Measure | |
serine peptidase inhibitor, Kunitz type 1 | Outcome Measure | |
suppression of tumorigenicity 14 (colon carcinoma) | Outcome Measure | |
T-Cell differentiation antigen CD8 | Outcome Measure | |
T-cell surface antigen CD4 | Outcome Measure | |
vitronectin | Detailed Description, Outcome Measure |
Development Status
Summary Table
Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
---|---|---|---|---|---|---|---|
COVID 2019 infections | SARS-COV-2 | Prevention | Research | Russia | Parenteral / unspecified | Biocad | 23 Mar 2020 |
Commercial Information
Involved Organisations
Organisation | Involvement | Countries |
---|---|---|
Biocad | Originator | Russia |
Biocad | Owner | Russia |
Licensing Availability
Licensing Organisation | Available Indication | Available Phase | Region | Date |
---|---|---|---|---|
Biocad | - | Unspecified | - | 23 Mar 2020 |
Future Events
Expected Date | Event Type | Description | Updated |
---|---|---|---|
30 Apr 2020 | Trial Update | Biocad plans a first preclinical trial in COVID-2019 infections (Prevention) in April 2020 [1] | 30 Mar 2020 |
Development History
Event Date | Update Type | Comment |
---|---|---|
23 Dec 2021 | Biomarker Update | Biomarkers information updated Updated 25 Dec 2021 |
26 Mar 2020 | Licensing Status | COVID-19 mRNA vaccine - BIOCAD is available for licensing as of 23 Mar 2020. https://biocadglobal.com/partnership.html Updated 26 Mar 2020 |
23 Mar 2020 | Phase Change | Early research in COVID-2019 infections (Prevention) in Russia (parenteral) [1] Updated 26 Mar 2020 |
19 Mar 2020 | Trial Update | Biocad plans a first preclinical trial in COVID-2019 infections (Prevention) in April 2020 [1] Updated 30 Mar 2020 |
References
-
BIOCAD started working on mRNA vaccine against coronavirus.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG